The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%, till 2030

---

Roots Analysis has done a detailed study on Microbial Contract Biomanufacturing Market, 2020-2030, covering key aspects of the industry and identifying potential future growth opportunities.

 

To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this link

 

Key Market Insights

• Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems
• Majority of the players have the necessary infrastructure / capability to produce different biologics, primarily proteins, at all scales using bacterial / yeast expression vectors
• The market features the presence of several well-established players across the globe; the US, the UK and Germany emerged as current hubs for production of biologics using microbial strains
• Several service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective service portfolio and maintain a competitive edge in the industry
• The growth trend of outsourcing microbial manufacturing operations is evident from the rise in recent partnership activity, as well as expansion initiatives undertaken by CMOs to meet the growing demand for novel biologics
• Big pharma players have also made significant investments in this domain through establishment of new facilities, entering into strategic collaborations and undertaking financial investments
• Future growth of the market is likely to be driven by increased adoption of novel biologics that are produced via microbial systems; we expect the service-based revenues to grow at a CAGR of over 8%
• In the long term, the projected opportunity for contract biomanufacturing is anticipated to be distributed across contract service providers of different sizes, scales of manufacturing and key geographical regions

 

For more information, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

 

Table of Contents

 

1.         PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines                     

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1        Chapter Overview

3.2.       Overview of Biopharmaceuticals

 

3.3.       Expression Systems Used for Biopharmaceutical Production

3.3.1.    Microbial Expression Systems

3.3.1.1. Bacterial Expression Systems

3.3.1.2. Fungal Expression Systems

3.3.1.3. Yeast Expression Systems                   

3.3.2.    Mammalian versus Microbial Expression Systems

 

3.4.       Microbial Manufacturing Process

3.4.1.    Cell Banking

3.4.2.    Upstream Processing

3.4.3.    Fermentation

3.4.4.    Downstream Processing

 

3.5.       Overview of Contract Manufacturing

3.6.       Need for Outsourcing Microbial Biomanufacturing Operations

3.7.       Commonly Outsourced Microbial Biomanufacturing Operations

3.8.       Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing                                        Operations

3.9.       Key Considerations while Selecting a CMO Partner

3.10.     Concluding Remarks     

 

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Microbial Contract Biomanufacturing Market: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Location of Headquarters

4.2.4.    Analysis by Location of Manufacturing Facility

4.2.5.    Analysis by Scale of Operation

4.2.6.    Analysis by Type of Biologic

4.2.7.    Analysis by Type of Expression System Used

4.2.8.    Analysis by Type of Fermenter

4.2.9.    Analysis by Type of Service(s) Offered

4.2.10.  Analysis by Regulatory Accreditations / Certifications

4.3.       Regional Analysis

4.3.1.    Analysis by North America

4.3.2.    Analysis by Europe

4.3.3.    Analysis by Asia Pacific

4.3.4.    Analysis by Middle East and North Africa

 

5.         COMPANY COMPETITIVENESS ANALYSIS

5.1.       Chapter Overview

5.2.       Assumptions and Key Parameters

5.3.       Methodology

5.4.       Competitiveness Analysis

5.4.1.    Competitiveness Analysis: Companies in North America

5.4.2.    Competitiveness Analysis: Companies in Europe

5.4.3.    Competitiveness Analysis: Companies in Asia Pacific    

 

6.         COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Microbial Contract Biomanufacturers based in North America

6.2.1.    AGC Biologics

6.2.1.1. Company Overview

6.2.1.2. Service Portfolio

6.2.1.3. Manufacturing Capabilities and Facilities

6.2.1.4. Recent Developments and Future Outlook

           

6.2.2.    Aldevron

6.2.2.1. Company Overview

6.2.2.2. Service Portfolio

6.2.2.3. Manufacturing Capabilities and Facilities

6.2.2.4. Recent Developments and Future Outlook

6.2.3.    BioVectra

6.2.3.1. Company Overview

6.2.3.2. Service Portfolio

6.2.3.3. Manufacturing Capabilities and Facilities

6.2.3.4. Recent Developments and Future Outlook

 

6.2.4.    Ology Bioservices

6.2.4.1. Company Overview

6.2.4.2. Service Portfolio

6.2.4.3. Manufacturing Capabilities and Facilities

6.2.4.4. Recent Developments and Future Outlook

 

6.3.       Microbial Contract Biomanufacturers Based in Europe

6.3.1.    Eurogentec

6.3.1.1. Company Overview

6.3.1.2. Service Portfolio

6.3.1.3. Manufacturing Capabilities and Facilities

6.3.1.4. Recent Developments and Future Outlook

 

6.3.2.    Northway Biotechpharma

6.3.2.1. Company Overview

6.3.2.2. Service Portfolio

6.3.2.3. Manufacturing Capabilities and Facilities

6.3.2.4. Recent Developments and Future Outlook

 

6.3.3.    Porton Biopharma

6.3.3.1. Company Overview

6.3.3.2. Service Portfolio

6.3.3.3. Manufacturing Capabilities and Facilities

6.3.3.4. Recent Developments and Future Outlook

           

6.4.       Microbial Contract Biomanufacturers Based in Asia Pacific

6.4.1.    EirGenix

6.4.1.1. Company Overview

6.4.1.2. Service Portfolio

6.4.1.3. Manufacturing Capabilities and Facilities

6.4.1.4. Recent Developments and Future Outlook

 

6.4.2.    Etinpro

6.4.2.1. Company Overview

6.4.2.2. Service Portfolio

6.4.2.3. Manufacturing Capabilities and Facilities

6.4.2.4. Recent Developments and Future Outlook

 

6.4.3.    Stelis Biopharma

6.4.3.1. Company Overview

6.4.3.2. Service Portfolio

6.4.3.3. Manufacturing Capabilities and Facilities

6.4.3.4. Recent Developments and Future Outlook

 

7.         RECENT PARTNERSHIPS

7.1.       Chapter Overview

7.2.       Partnership Models

7.3.       Microbial Contract Biomanufacturers: Recent Partnerships

7.3.1.    Analysis by Year of Partnerships

7.3.2.    Analysis by Type of Partnership Model

7.3.3.    Analysis by Scale of Operation

7.3.4.    Analysis by Type of Biologic

7.3.5.    Analysis by Focus Area

7.3.6.    Analysis by Target Therapeutic Area

 

7.3.7.    Analysis by Region

7.3.7.1. Country-Wise Distribution

7.3.7.2. Intercontinental and Intracontinental Agreements

 

7.3.8.    Most Active Players: Analysis by Number of Partnerships

 

7.4.       Microbial Contract Biomanufacturers: Mergers and Acquisitions

7.4.1.    Analysis by Year of Merger / Acquisition

7.4.2.    Analysis by Type of Acquisition 

7.4.3.    Regional Analysis 

7.4.3.1. Continent-wise Distribution 

7.4.3.2. Country-wise Distribution 

7.4.3.3. Intercontinental and Intracontinental Deals 

  

7.4.4.    Most Active Players: Analysis by Number of Acquisitions

7.4.5.    Analysis by Key Value Drivers  

7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers

 

8.         RECENT EXPANSIONS

8.1.       Chapter Overview

8.2.       Microbial Contract B